WILMINGTON, N.C.–(BUSINESS WIRE)–PPD, Inc. (Nasdaq:PPD), has been recognized as a top employer in Bulgaria, adding to the global contract research organization’s growing list of accolades as an employer of choice around the world.
PPD was recognized as a top 50 desirable employer in Bulgaria, according to the second annual Employer of Choice Survey organized by the employer brand and business consulting agency To The Top. The organization selected employers for the annual list based on a survey of 8,092 working professionals across 176 cities in Bulgaria.
PPD also was ranked in the top 100 most desirable employers among students in Bulgaria in To The Top’s 2020 Graduate Survey of over 5,830 students from 51 universities. Bulgaria has a large pool of highly trained health care professionals with extensive language capabilities, and PPD has multiple internships opportunities with medical and pharmacy schools in the area.
“PPD’s strong company culture, focused on helping customers deliver life-changing medicines for patients, and our commitment to employee development and professional growth, make the company a desirable workplace for talented professionals,” said Hristo Sabev, senior director, clinical management and a managing director of PPD in Bulgaria. “Engaging and empowering employees helps PPD consistently deliver value for our customers and their important drug development programs. We are proud of the strong reputation our company has established as a leading employer in Bulgaria.”
PPD’s office in Sofia employs more than 1,200 professionals, including physicians, pharmacists, nurses and medical specialists who provide Phase I-IV clinical trial management and support, site and patient access solutions, and regulatory affairs services. PPD has had operations in Bulgaria since 2009.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 24,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest annual report on Form 10-K and Quarterly Report on form 10-Q, which is available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.